Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Cathie Wood’s ARK Investment Management sharply increased its exposure to AI-driven biotechnology and cryptocurrency during ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

The average one-year price target for Recursion Pharmaceuticals (NasdaqGS:RXRX) has been revised to $7.14 / share. This is an increase of 10.53% from the prior estimate of $6.46 dated December 3, 2025 ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

The Ethereum Foundation has set a new technical roadmap prioritizing security over speed for zero-knowledge Ethereum Virtual ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

On the buying side, ARK made a notable purchase of 17,386 shares of Coinbase Global Inc (PRE-REINCORPORATION) (NASDAQ:COIN) across its ARKK, ARKW, and ARKF ETFs, with a total dollar value of ...